Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SIGNIA

Financiado

Cerrado

SIGNIA An innovative drug discovery platform for rapid identification and valid...

SIGNIA An innovative drug discovery platform for rapid identification and validation of antimicrobial applications in available pharmaceutical resources and drugs open for repurposing. The economic and social burden of infections is being enhanced by the emergence of drug-resistant pathogens. This phenomenon is outpacing the industry’s capacity for drug discovery and development. Antimicrobial resistance is cost... ver más

30/11/2018

SIGNIATHERAP

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

SIGNIA THERAPEUTICS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

SIGNIATHERAP

50.00K€ | Lider

IACTIVE INTELLIGENT SOLUTION...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AnLeadOp Antibiotic Lead Optimization 150K€ Cerrado

PID2019-108643GA-I00 ABORDANDO LA RESISTENCIA ANTIMICROBIANA MEDIANTE ESTRUCTURAS... 85K€ Cerrado

TIPAT Training towards Personalized Antibiotic Treatment 4M€ Cerrado

ANTIPATHOGN Identification and validation of novel drug targets in Gram... 8M€ Cerrado

IN-ARMOR THERAPEUTIC EPIGENETIC ENHANCEMENT OF THE INNATE IMMUNITY TO... 6M€ Cerrado

SAF2017-85785-R UNA APROXIMACION METAGENOMICA NOVEDOSA PARA COMBATIR LAS CRE... 194K€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2018-07-16
Fecha Fin: 2018-11-30

Líder del proyecto

SIGNIA THERAPEUTICS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The economic and social burden of infections is being enhanced by the emergence of drug-resistant pathogens. This phenomenon is outpacing the industry’s capacity for drug discovery and development. Antimicrobial resistance is costing the EU today €1.5 billion and 25,000 deaths annually. Developing de novo classical drugs is very costly and time consuming, and for every new drug released a resistant strain has rapidly emerged. This paradigm is hindering our ability to respond to outbreaks. Among causative organisms, viruses pose a major threat, being responsible for the outbreaks impacting the world in the past decade (SARS, Influenza A, MERS, etc). Although some antivirals have been developed for them, they lose their efficacy rapidly due to the high mutation rate of viruses, which alters the antigenic features originally used to develop the drug. Thus, there is an urgent need for novel discovery methods that allow to accelerate the development of broad-spectrum and mutability-independent antimicrobials. In response, Signia Therapeutics has developed and validated a drug discovery platform for fast identification of compounds with antimicrobial activity. Instead of selecting drugs that target pathogen determinants, it selects drugs that target determinants of the infected cell. This method offers key advantages: i) avoids the impact of microbe intrinsic mutability; ii) broad spectrum drugs can be identified. Since the platform seeks for antimicrobial applications among drugs already commercialized (repurposing) and among pharma libraries (recycling), drug discovery becomes faster, safer and cost-efficient. Having reached the functional stage (TRL6), this project encloses the roadmap to finalise the platform’s development and its preparation for market. Once completed, this project will have huge impacts for society (better management of infections and preparedness against outbreaks), and for our company (expected ROI of €2.1 from this project after 5 years).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores